Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy

Alfonso Quintás-Cardama, Hagop Kantarjian, Susan O'Brien, Elias Jabbour, Gautam Borthakur, Farhad Ravandi, Srdan Verstovsek, Jianqin Shan, Jorge Cortes

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

We investigated the impact of carrying more than one BCRABL1 mutation in 207 patients with chronic myeloid leukemia (102 chronic, 61 accelerated, and 44 blast phase) post-imatinib failure. Seven (8%) of 92 patients carrying mutations had more than one mutation: 4 (4%) in chronic phase, 2 (2%) in accelerated phase, and one (1%) in blast phase. The cytogenetic response rate to second generation TKIs for patients with no, one, or more than one mutation was 88%, 69%, 50% (P=0.03) in chronic phase, 54%, 42%, 50% in accelerated phase (P=0.67), and 35%, 25%, 0% (P=0.63) in blast phase, respectively. No differences were observed in event free survival or overall survival in accelerated or blast phase according to their mutational status. However, the 4-year event free survival rates among patients in chronic phase with no, one, or more than one BCR-ABL1 mutation were 56%, 49%, and 0%, respectively (P=0.02), with overall survival rates of 91%, 69%, and 75%, respectively (P=0.13). In conclusion, patients with more than one BCR-ABL1 mutation fare worse than those with no or one mutation.

Original languageEnglish (US)
Pages (from-to)918-921
Number of pages4
JournalHaematologica
Volume96
Issue number6
DOIs
StatePublished - Jun 1 2011
Externally publishedYes

Keywords

  • ABL1 mutation
  • CML
  • Multiple mutations
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy'. Together they form a unique fingerprint.

  • Cite this

    Quintás-Cardama, A., Kantarjian, H., O'Brien, S., Jabbour, E., Borthakur, G., Ravandi, F., Verstovsek, S., Shan, J., & Cortes, J. (2011). Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Haematologica, 96(6), 918-921. https://doi.org/10.3324/haematol.2010.039321